3-{2-[(2,3-dihydroxy-propyl)-methyl-amino]-ethyl}-8-[2-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-ethyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-{2-[(2,3-dihydroxy-propyl)-methyl-amino]-ethyl}-8-[2-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-ethyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
• 英文别名: 3-[2-[2,3-Dihydroxypropyl(methyl)amino]ethyl]-8-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
• 化学式: C₃₀H₄₈N₄O₃
• 分子量: 512.736
• InChiKey: ZITKSXQYHIMCMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  70.5
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  8-[2-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-ethyl]-3-(2-methylamino-ethyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 、 缩水甘油 以 异丙醇 为溶剂， 反应 48.0h， 生成 3-{2-[(2,3-dihydroxy-propyl)-methyl-amino]-ethyl}-8-[2-(6,6-dimethyl-bicyclo[3.1.1]hept-2-yl)-ethyl]-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  Hydronopol derivatives as agonists on human ORL1 receptors

  摘要：

  本发明涉及一组氢诺普尔衍生物，它们是人ORL1（痛敏素）受体的激动剂。本发明还涉及这些化合物的制备方法，以及含有至少一种这些新型氢诺普尔衍生物作为活性成分的药理活性量的药物组合物，以及这些药物组合物用于治疗涉及ORL1受体的疾病的使用。本发明涉及通式（1）的化合物，其中符号的含义如说明书中所述。

  公开号：

  US20050131004A1

文献信息

• HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORLI RECEPTORS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1694675A2

  公开（公告）日：2006-08-30
• US7241770B2
  申请人：——

  公开号：US7241770B2

  公开（公告）日：2007-07-10
• [EN] HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS<br/>[FR] DERIVES D'HYDRONOPOL UTILISES COMME AGONISTES DES RECEPTEURS ORL1 HUMAINS
  申请人：SOLVAY PHARM GMBH

  公开号：WO2005058890A2

  公开（公告）日：2005-06-30

  The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.
• Hydronopol derivatives as agonists on human ORL1 receptors
  申请人：Mentzel Matthias

  公开号：US20050131004A1

  公开（公告）日：2005-06-16

  The invention relates to a group of hydronopol derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel hydronopol derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.

  本发明涉及一组氢诺普尔衍生物，它们是人ORL1（痛敏素）受体的激动剂。本发明还涉及这些化合物的制备方法，以及含有至少一种这些新型氢诺普尔衍生物作为活性成分的药理活性量的药物组合物，以及这些药物组合物用于治疗涉及ORL1受体的疾病的使用。本发明涉及通式（1）的化合物，其中符号的含义如说明书中所述。